Altimmune stock price forecast: brace for more ALT volatility

February 28, 2024 12:49 AM PST | By Invezz
 Altimmune stock price forecast: brace for more ALT volatility
Image source: Invezz

Altimmune (NASDAQ: ALT) stock price continued its short squeeze this week, soaring to a high of $14.52, its highest point since February 6th last year. The company’s stock surged by more than 580% from its lowest level in 2023. This surge has brought its total market cap to over $608 million.

Short squeeze continues

ALT stock price has jumped sharply in the past few months in a high-volume environment. The most recent data shows that the three-month volume rose to $12.6 million. This week, the daily volume has moved to over $36 million. A few months ago, its total daily was averaging less than 1 million shares.

Altimmune shares have surged as investors cheered its progress in developing a weight loss drug. In a statement in December, analysts at JMP Securities noted that the drug was doing better than that developed by other companies.

Therefore, if the ongoing trial brings strong results, analysts believe that Altimmune will become a good acquisition target by some of the bigger companies. 

There are signs that these healthcare giants are considering buyouts to enter into an industry that is growing rapidly. In December, Roche acquired Carmot in a $2.7 billion deal.

Altimmune shares also surged as Viking Therapeutics (VKTX) stock jumped after positive results for its drug. 

The other reason for this price action is that the company has become a target of short-sellers, which has triggered a short squeeze. 

In a report, Kerrisdale Capital noted that Altimmune’s drug, pemvidutide was still inferior compared to Ozempic and Mounjaro. The latter two, because of their first mover advantage, will continue doing well over time.

The short report also noted that the drug had worse side effects and that big and small companies are researching on tens of drugs. Novo Nordisk and Eli Lilly are continuing with further research to improve their existing products.

Also, there are substantial concerns about the side effects of these drugs, their costs, and their withdrawal symptoms. 

Altimmune stock price forecast

ALT chart by TradingView

The weekly chart shows that the ALT share price has been a bit volatile in the past few months. The Average True Range (ATR), which is a popular volatility indicator, has risen to 2, its highest point since May 2023. 

Now, the stock has jumped above the 200-week Exponential Moving Average (EMA) and crossed the crucial resistance point at $12.95, its highest level on January 8th of this year. 

Therefore, I suspect that this volatility will continue in the coming days as investors focus on the GLP drug industry. This means that the stock could see double-digit gains or losses in the coming days. If this happens, the key support and resistance points to watch will be at $10 and $17.50.

The post Altimmune stock price forecast: brace for more ALT volatility appeared first on Invezz


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


Sponsored Articles


Investing Ideas

Previous Next